A detailed history of Point72 Hong Kong LTD transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Point72 Hong Kong LTD holds 3,325 shares of SAGE stock, worth $35,311. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,325
Previous 10,934 69.59%
Holding current value
$35,311
Previous $236,000 73.73%
% of portfolio
0.0%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$18.62 - $26.95 $141,679 - $205,062
-7,609 Reduced 69.59%
3,325 $62,000
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $186,971 - $243,390
10,934 New
10,934 $236,000
Q2 2022

Aug 15, 2022

BUY
$27.52 - $37.99 $32,363 - $44,676
1,176 Added 13.44%
9,927 $321,000
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $138,839 - $206,654
4,521 Added 106.88%
8,751 $290,000
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $16,602 - $21,105
-448 Reduced 9.58%
4,230 $180,000
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $188,336 - $268,376
4,678 New
4,678 $207,000
Q2 2020

Aug 14, 2020

SELL
$25.95 - $43.15 $10,691 - $17,777
-412 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$26.15 - $77.24 $25,836 - $76,313
-988 Reduced 70.57%
412 $12,000
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $21,063 - $54,169
350 Added 33.33%
1,400 $101,000
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $113,354 - $153,487
808 Added 333.88%
1,050 $147,000
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $38,199 - $44,307
242 New
242 $44,000
Q4 2018

Feb 14, 2019

SELL
$81.94 - $139.71 $49,409 - $84,245
-603 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$138.11 - $169.04 $57,453 - $70,320
416 Added 222.46%
603 $85,000
Q2 2018

Aug 14, 2018

BUY
$140.36 - $175.76 $26,247 - $32,867
187 New
187 $29,000
Q4 2017

Feb 14, 2018

SELL
$60.72 - $167.34 $4,068 - $11,211
-67 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $4,113 - $5,930
67
67 $4,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $631M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.